The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases

Warren, N. M.; Piggott, M. A.; Lees, A. J.; Burn, D. J.
June 2007
Journal of Neurology, Neurosurgery & Psychiatry;Jun2007, Vol. 78 Issue 6, p571
Academic Journal
Background: Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder involving motor and cognitive dysfunction. Currently, there is no effective treatment either for symptomatic relief or disease modification. This relates, in part, to a lack of knowledge of the underlying neurochemical abnormalities, including cholinergic receptor status in the basal ganglia. Aim: To measure muscarinic M2 and M4 receptors in the basal ganglia in PSP. Methods: The muscarinic M2 (presynaptic) and M4 (postsynaptic) receptors in the striatum, pallidum and adjacent insular cortex were autoradiographically measured in pathologically confirmed cases of PSP (n = 18), and compared with cases of Lewy body dementias (LBDs; n = 45), Alzheimer's disease (AD; n = 39) and controls (n = 50). Results: In cases of PSP, there was a reduction in M2 and M4 receptors in the posterior caudate and putamen compared to controls, but no significant changes in the pallidum. Cases with AD showed lower M2 receptors in the posterior striatum. Groups with (BD and AD showed higher M2 binding in the insular cortex compared with controls. Conclusions: The results suggest loss of posterior striatal cholinergic interneurones in PSP, and reduction in medium spiny projection neurones bearing M4 receptors. These results should be taken in the context of more widespread pathology in PSP, but may have implications for future trials of cholinergic treatments.


Related Articles

  • Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Hirano, Shigeki; Shinotoh, Hitoshi; Shimada, Hitoshi; Aotsuka, Akiyo; Tanaka, Noriko; Ota, Tsuneyoshi; Sato, Koichi; Ito, Hiroshi; Kuwabara, Satoshi; Fukushi, Kiyoshi; Irie, Toshiaki; Suhara, Tetsuya // Brain: A Journal of Neurology;Jul2010, Vol. 133 Issue 7, p2058 

    Corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia are all part of a disease spectrum that includes common cognitive impairment and movement disorders. The aim of this study was to characterize brain cholinergic deficits in these disorders. We measured brain...

  • Announcement.  // JAMA: Journal of the American Medical Association;8/9/95, Vol. 274 Issue 6, p512i 

    Announces the National Institute of Neurological Disorders and Stroke's (NINDS) call for patients with newly diagnosed Parkinson's disease and progressive supranuclear palsy for a neuroprotective trial involving a free radical scavenger. Requirements; Contact information.

  • Frequency, distribution and characteristics of progressive supranuclear palsy in Italy: preliminary observations. Brusa, A.; Cammarata, S. // Neurological Sciences;Sep2002 Supplement 2, Vol. 23, pS63 

    We report the number of pathologically proven cases of progressive supranuclear palsy, described in the Italian neurological literature from 1961 until now. A discussion of the diagnostic value of downward gaze palsy is made. A comparison with the number of similar cases described in the rest of...

  • Amiodarone/flunarizine interaction.  // Reactions Weekly;9/25/2010, Issue 1320, p9 

    The article describes the case of a 74-year-old woman who developed a progressive supranuclear palsy (PSP)-like syndrome while undergoing amiodarone and flunarizine treatment.

  • Amiodarone/flunarizine.  // Reactions Weekly;2/20/2010, Issue 1289, p7 

    The article describes the case of a 74-year-old woman who developed progressive supranuclear palsy-like syndrome while receiving treatment with amiodarone and flunarizine.

  • Hummingbird sign in progressive supranuclear palsy disease. Pandey, Sanjay // Journal of Research in Medical Sciences;Feb2012, Vol. 17 Issue 2, p197 

    Progressive supranuclear palsy (PSP) is characterized by slowness, rigidity, bradykinesia, repeated falls, downgaze limitation and dementia. Midbrain atrophy on magnetic resonance imaging is highly suggestive of PSP and is described as "hummingbird sign". This sign is very helpful in...

  • Primary antiphospholipid antibody syndrome masquerading as progressive supranuclear palsy. Reitblat, T; Polishchuk, I; Dorodnikov, E; Aladjem, Z; Turiansky, L; Zamir, D; Kahana, E // Lupus;2003, Vol. 12 Issue 1, p67 

    We report a case of a patient with clinical features of progressive supranuclear palsy and raised titres of anticardiolipin antibodies in blood, thrombocytopenia and livedo reticularis on skin. Magnetic resonance imaging of brain and isotope scan of brain were distinctive of vascular disorder.

  • A case of spontaneous arm levitation in progressive supranuclear palsy. Gunal, D.İ.; Ağan, K.; Aktan, S. // Neurological Sciences;Dec2000, Vol. 21 Issue 6, p405 

    Progressive supranuclear palsy is one of the parkinsonial syndromes causing atypical parkinsonism. In recent reports, other than subcortical involvement, also cortical structures have been shown to be involved in progressive supranuclear palsy patients. One of the clinical presentations of this...

  • Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Testa, D.; Monza, D.; Ferrarini, M.; Soliveri, P.; Girotti, F.; Filippini, G. // Neurological Sciences;Jun2001, Vol. 22 Issue 3, p247 

    In order to identify early clinical features and survival predictors of supranuclear palsy (PSP) and multiple system atrophy (MSA), we compared the disease course of patients consecutively referred between 1987 and 1999 and followed to December 1999. Thirty-nine PSP and 74 MSA patients were...


Read the Article


Sign out of this library

Other Topics